AXONIS Therapeutics, Inc.

AXONIS Therapeutics, Inc. , based in the US, develops innovative therapies targeting the KCC2 protein to enhance inhibition in the central nervous system, focusing on treating neurological disorders such as epilepsy and chronic pain. AXONIS Therapeutics specializes in developing innovative therapies aimed at KCC2, a key mediator in the central nervous system. Founded in 2019 and headquartered in Boston, US, the company has engaged in 4 significant deals.

The latest funding round, a Series A completed in October 2024, raised USD 46. 000 mn, co-led by investors Cormorant Asset Management and VenBio Partners, with notable participation from Alexandria Venture Investments and BoxOne Ventures. The founders of the company include Bob Yant, Joanna Stanicka, Mark Pinney, Patrick Carew, and Shane Hegarty, with Joanna Stanicka also serving as the CEO. Axonis Therapeutics focuses on developing therapies that target KCC2, with its leading product AXN-027 being an oral KCC2 potentiator that aims to restore functional inhibition and address neurological disorders such as epilepsy and chronic pain.

Their products draw upon research from prestigious institutions, including Boston Children's Hospital and Harvard University, ensuring a solid scientific foundation. The company is set to launch first-in-human clinical trials in 2024, primarily targeting markets in North America and Europe to support patients suffering from debilitating neurological conditions. Axonis Therapeutics has raised a total of USD 46. 000 mn through an oversubscribed Series A funding round, which is aimed at advancing its therapeutic programs.

The company's revenue model relies on partnerships with pharmaceutical firms and research institutions, supplemented by grants and awards that bolster their developmental activities. As their products are still under development, transactions focus on strategic collaborations and research agreements rather than direct sales. Specific pricing plans for AXN-027 have not been unveiled, but the firm's financial strategy emphasizes rigorous scientific validation and securing partnerships to promote market access. In October 2024, AXONIS Therapeutics raised USD 46.

000 mn in a Series A funding to develop next-generation compounds targeting KCC2 for psychiatric and neurodevelopmental disorders. The funds will be utilized to support the advancement of these new therapeutic options. The company plans to expand its market presence in North America and Europe, accelerating their product development paths with imminent clinical trials. The strategic focus is on enhancing their pipeline to address further neurological conditions, leveraging the financial backing received to expedite these initiatives.